Fig. 5: Loss of HAT1 expression leads to the IGF1R-dependent activation of the MAPK signaling pathway, which confers BRAFi resistance in melanoma cells. | Oncogenesis

Fig. 5: Loss of HAT1 expression leads to the IGF1R-dependent activation of the MAPK signaling pathway, which confers BRAFi resistance in melanoma cells.

From: Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R

Fig. 5

a Immunoblotting for phospho- and the total ERK in A375 and SKMEL-28 cells expressing nonspecific NS or HAT1 shRNAs. b Relative IGF1R mRNA levels in A375 and SKMEL-28 cells expressing nonspecific NS or HAT1 shRNAs were analyzed by qRT-PCR. Actin was used as an internal control. c Immunoblotting for phospho- and the total IGF1R in A375 and SKMEL-28 cells expressing nonspecific NS or HAT1 shRNAs. d, f A375 or SKMEL-28 cells expressing a nonspecific (NS) shRNA or HAT1 shRNAs were treated with DMSO, BRAF inhibitor vemurafenib (1 μM), IGF1R inhibitor, BMS-754807 (0.1 μM) and ERK inhibitor, SCH772984 (0.2 μM), which was analyzed by soft-agar assay. e, g Relative colony size for data presented in panels d and f. Data are presented as the mean ± SEM, *p < 0.05, **p < 0.01, calculated using Student’s t test.

Back to article page